Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1325915rdf:typepubmed:Citationlld:pubmed
pubmed-article:1325915lifeskim:mentionsumls-concept:C0927232lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C0075632lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C0530967lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C1261322lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C1705920lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C0597358lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C0205453lld:lifeskim
pubmed-article:1325915lifeskim:mentionsumls-concept:C0049095lld:lifeskim
pubmed-article:1325915pubmed:issue2lld:pubmed
pubmed-article:1325915pubmed:dateCreated1992-10-13lld:pubmed
pubmed-article:1325915pubmed:abstractTextThe ability of three 5-HT1 receptor agonists, 5-HT (5-hydroxytryptamine), 5-CT (5-carboxyamidotryptamine) and sumatriptan to inhibit the binding of [3H]5-HT, in the presence of cyanopindolol and mesulergine, from cerebral cortical and/or caudate membranes in seven species (dog, guinea-pig, rabbit, pig, human, hamster and calf) has been investigated. Under the experimental conditions used, 5-CT and sumatriptan consistently yielded displacement curves best fit to a two-site model whereas 5-HT always gave a monophasic displacement curve. The pIC50 values obtained with 5-HT displacement gave a mean of 8.1 +/- 0.1 (mean +/- S.E.M.). In contrast the biphasic displacement curves for 5-CT and sumatriptan yielded high and low affinity pIC50 values of 8.3 +/- 0.1, 5.5 +/- 0.1 and 7.6 +/- 0.1, 5.0 +/- 0.1, respectively. These data indicate that under these experimental conditions the high affinity component labelled by [3H]5-HT is the same receptor subtype, previously denoted the 5-HT1D receptor, in all seven species.lld:pubmed
pubmed-article:1325915pubmed:languageenglld:pubmed
pubmed-article:1325915pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1325915pubmed:citationSubsetIMlld:pubmed
pubmed-article:1325915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1325915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1325915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1325915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1325915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1325915pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1325915pubmed:statusMEDLINElld:pubmed
pubmed-article:1325915pubmed:monthMarlld:pubmed
pubmed-article:1325915pubmed:issn0014-2999lld:pubmed
pubmed-article:1325915pubmed:authorpubmed-author:MiddlemissD...lld:pubmed
pubmed-article:1325915pubmed:authorpubmed-author:StantonJ AJAlld:pubmed
pubmed-article:1325915pubmed:authorpubmed-author:ChauhanN SNSlld:pubmed
pubmed-article:1325915pubmed:authorpubmed-author:BeerM SMSlld:pubmed
pubmed-article:1325915pubmed:authorpubmed-author:BevanYYlld:pubmed
pubmed-article:1325915pubmed:issnTypePrintlld:pubmed
pubmed-article:1325915pubmed:day24lld:pubmed
pubmed-article:1325915pubmed:volume213lld:pubmed
pubmed-article:1325915pubmed:ownerNLMlld:pubmed
pubmed-article:1325915pubmed:authorsCompleteYlld:pubmed
pubmed-article:1325915pubmed:pagination193-7lld:pubmed
pubmed-article:1325915pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:meshHeadingpubmed-meshheading:1325915-...lld:pubmed
pubmed-article:1325915pubmed:year1992lld:pubmed
pubmed-article:1325915pubmed:articleTitleAn investigation of the 5-HT1D receptor binding affinity of 5-hydroxytryptamine, 5-carboxyamidotryptamine and sumatriptan in the central nervous system of seven species.lld:pubmed
pubmed-article:1325915pubmed:affiliationMerck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, U.K.lld:pubmed
pubmed-article:1325915pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1325915lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1325915lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1325915lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1325915lld:pubmed